{"$schema": "https://iptc.org/std/ninjs/ninjs-schema_3.2.json", "uri": "urn:newsml:wireva.mib.news:item:b9da9f33-00e7-4f75-9dd0-28ca28122c67", "type": "text", "profile": "standard", "version": "1", "versioncreated": "2026-10-10T19:05:00.681577Z", "firstcreated": "2026-10-10T19:01:36.958866Z", "pubstatus": "usable", "urgency": 5, "language": "en", "headline": "Immunotherapy Before Surgery Eliminates Recurrence in Bowel Cancer Trial", "byline": "Kelsey Sawyer", "located": "United States", "copyrightholder": "Haydamax OÜ", "copyrightnotice": "Wireva / Science Official", "usageterms": "Monitoring item. Headline, short extract and the source link may be shown. Do not republish the full text.", "description_text": "In the NEOPRISM-CRC trial, 32 patients with a specific genetic form of stage two or three bowel cancer received pembrolizumab before surgery instead of post-surgery chemotherapy. After nearly three years, none experienced recurrence, even those with traces of disease remaining after treatment.", "altids": {"mosaic": "b9da9f33-00e7-4f75-9dd0-28ca28122c67", "story": "54415ee3-c89a-424f-9891-59a95c001059", "slug": "immunotherapy-before-surgery-eliminates-recurrence-in-bowel-cancer-trial"}, "subject": [{"name": "Health", "rel": "direct", "literal": "health", "code": "medtop:07000000", "scheme": "http://cv.iptc.org/newscodes/mediatopic/", "uri": "http://cv.iptc.org/newscodes/mediatopic/07000000"}], "place": [{"name": "United States", "literal": "us", "code": "US", "scheme": "http://cv.iptc.org/newscodes/countrycodes/"}], "person": [], "organisation": [], "genre": [{"name": "Standard story", "literal": "standard"}], "service": [{"name": "Wireva", "literal": "wireva"}], "body_text": "In the NEOPRISM-CRC trial, 32 patients with a specific genetic form of stage two or three bowel cancer received pembrolizumab before surgery instead of post-surgery chemotherapy. After nearly three years, none experienced recurrence, even those with traces of disease remaining af", "extra_body_note": "Extract only — see rights.class = link_only.", "associations": {"featuremedia": {"uri": "urn:newsml:wireva.mib.news:media:2d7d6c4d-e501-4a40-a8b0-21ee62e7a948", "type": "picture", "version": "1", "pubstatus": "usable", "headline": "Bowel cancer “melted away” after immunotherapy, then stayed away", "description_text": "Immunotherapy Before Surgery Eliminates Recurrence in Bowel Cancer Trial", "copyrightholder": "en.wikipedia.org", "copyrightnotice": "Cancer immunotherapy", "usageterms": "File-level licence not yet resolved from Commons; fetch the original for exact terms.", "altids": {"wireva": "2d7d6c4d-e501-4a40-a8b0-21ee62e7a948"}, "extra": {"wireva:delivery_mode": "preview_and_link", "wireva:rights": {"licence": "Wikimedia — licence per file", "licence_url": "https://commons.wikimedia.org/wiki/Commons:Reusing_content_outside_Wikimedia", "licence_raw": "Wikipedia page image", "licence_verified_at": "2026-10-10T19:05:00.696504Z", "attribution_required": true, "attribution_text": "Cancer immunotherapy", "redistribution_allowed": false, "commercial_use_allowed": false, "modifications_allowed": false, "share_alike_required": false}, "wireva:provenance": {"creator": "", "source_name": "en.wikipedia.org", "source_url": "https://en.wikipedia.org/wiki/Cancer_immunotherapy", "source_page_url": "https://en.wikipedia.org/wiki/Cancer_immunotherapy", "our_page_url": "https://scienceofficial.org/medicine/immunotherapy-before-surgery-eliminates-recurrence-in-bowel-cancer-trial/"}, "wireva:role": "lead"}, "renditions": {"preview": {"href": "https://nbg1.your-objectstorage.com/ckln/image-assets/71ebdb7a0b93a4d1639bfb77d5873e3a38f67ab11647baacc8b97763db9e18f0.jpg", "mimetype": "image/jpeg", "width": 1280, "height": 868}, "source": {"href": "https://en.wikipedia.org/wiki/Cancer_immunotherapy", "mimetype": "image/jpeg"}}}}, "extra": {"wireva:story": {"uri": "urn:newsml:wireva.mib.news:story:54415ee3-c89a-424f-9891-59a95c001059", "slug": "immunotherapy-before-surgery-eliminates-recurrence-in-bowel-cancer-trial-20261010", "status": "developing", "languages": ["en"], "item_count": 1, "is_breaking": false}, "wireva:rights": {"class": "link_only", "redistribution_allowed": false, "commercial_use_allowed": false, "modifications_allowed": true, "share_alike_required": false, "attribution_required": true, "attribution_text": "Wireva / Science Official", "canonical_required": true, "canonical_url": "https://scienceofficial.org/medicine/immunotherapy-before-surgery-eliminates-recurrence-in-bowel-cancer-trial/", "linkback_required": true, "licence": "", "licence_url": "", "licensor": "Haydamax OÜ", "valid_until": null, "excerpt_max_chars": 280, "decided_by_rule": "derivation_failed", "needs_review": true}, "wireva:provenance": {"production_method": "automated", "ai_stages": {"editing": true, "drafting": true, "headline": true, "discovery": true, "classification": true, "image_selection": true, "source_collection": true, "cross_source_comparison": true}, "model": "", "human_reviewed": false, "reviewed_by": "", "reviewed_at": null, "editorial_control": true, "editorial_responsibility": "Haydamax OÜ (Wireva)", "factchecked": false, "verification_status": "single_source", "independent_confirmations": 0, "official_source_used": false, "used_press_release": false, "public_interest": true, "ai_disclosure_required": true, "ai_disclosure_text": "This item was produced with AI assistance under the editorial responsibility of Haydamax OÜ.", "independence_check": {"status": "failed", "score": 0.886, "checked_at": "2026-10-10T19:05:00.693572Z"}}, "wireva:publication": {"name": "Science Official", "domain": "scienceofficial.org", "country": "US", "url": "https://scienceofficial.org/medicine/immunotherapy-before-surgery-eliminates-recurrence-in-bowel-cancer-trial/"}, "wireva:links": {"self": "https://wireva.mib.news/api/v1/items/b9da9f33-00e7-4f75-9dd0-28ca28122c67", "html": "https://wireva.mib.news/item/b9da9f33-00e7-4f75-9dd0-28ca28122c67/immunotherapy-before-surgery-eliminates-recurrence-in-bowel-cancer-trial/", "story": "https://wireva.mib.news/story/immunotherapy-before-surgery-eliminates-recurrence-in-bowel-cancer-trial-20261010/"}, "wireva:metrics": {"word_count": 643, "char_count": 4229, "reading_time_seconds": 302}}}